Biological Therapy for Psoriatic Arthritis in Clinical Practice: Outcomes Up to 2 Years

Abstract

Anti-tumor necrosis factor-α therapy, often combined with conventional disease-modifying antirheumatic drugs, appeared to have limited toxicity and persistent effectiveness for up to 2 years in a cohort of Finnish patients with severe peripheral PsA.

Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study

“…In previous studies, 12-30% of patients have discontinued their treatment within 1 year and 19-43% within 2 years of follow-up [3,6,7,9]. Our respective results of 20% and 28% serve as a confirmation to these previous findings.…”

“…This present study updates previous findings on TNF-inhibitor treatment among PsA patients based on the ROB-FIN register with extended follow-up and additional analyses on treatment response and persistence [6]. Although some previous literature on the subject exists, our study is the first to include golimumab.…”

“…A number of randomized controlled trials on the efficacy and safety of TNF-inhibitors in the treatment of PsA have been published and their pooled results suggest that TNF-inhibitors are both an effective and relatively safe therapy for PsA [2]. Several observational studies on the effectiveness and drug survival of TNFinhibitors in PsA, based on patient registries Denmark, Norway, Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/semarthrit Sweden, Finland, Spain, and UK, have been published [3][4][5][6][7][8][9][10]. In these studies, proportions of patients reaching good EULAR response at 6 months have ranged from 38 to 55 with no statistically significant association to concomitant methotrexate (MTX) therapy.…”

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

“…Although RCTs are considered the gold standard for assessing efficacy and safety of a specific therapeutic intervention, their results are often limited due to their brief follow-up Drug survival is considered a measure of therapeutic success as it is largely conditioned by drug efficacy and tolerance. Such reports, in overall, reflect the good survival profile of these agents in PsA patients, with rates of treatment discontinuation ranging from 12 to 30% at 12 months and from 19 to 43% at 24 months [4,8,12,13,[16][17][18]. Similar adherence has been shown for ETN therapy in PsA, with discontinuation rates between 14-19, 21-27 and 33-35% at 12, 24 and 36 months, respectively [12,13].…”

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

“…Data from clinical practice are needed to complement the trials and to assess their external validity (27). Published studies on patients with PsA treated with biologic drugs are, however, few (4, 8, 9, 28, 29). The present nationwide study of 764 patients with PsA followed up prospectively for up to 8 years in routine care represents the largest cohort and the longest observation time published to date.…”